

Table SI. Comparison of severity of dysphagia and nutritional status between groups.

Characteristic	Treatment		Statistic(χ^2 or F value)	P-value
	GTC + SYS (n=114)	SYS (n=114)		
Nutritional status at baseline			0.17	0.678 ^a
Moderate malnutrition	39 (34.2)	42 (36.8)		
Severe malnutrition	75 (65.8)	72 (63.2)		
Nutritional status at 4 weeks after the first cycle of SYS			156.18	<0.001 ^b
Moderate malnutrition	9 (7.9)	73 (64.0)		
Severe malnutrition	0 (0.0)	29 (25.4)		
Suspected malnutrition	58 (50.9)	12 (10.5)		
Well nourished	47 (41.2)	0 (0.0)		
Nutritional status at 8 weeks after the first cycle of SYS			150.20	<0.001 ^b
Moderate malnutrition	1 (0.9)	38 (33.3)		
Severe malnutrition	0 (0.0)	15 (13.2)		
Suspected malnutrition	14 (12.3)	53 (46.5)		
Well nourished	99 (86.8)	8 (7.0)		
Severity of dysphagia at baseline			0.76	0.684 ^a
1	8 (7.0)	6 (5.3)		
2	39 (34.2)	35 (30.7)		
3	67 (58.8)	73 (64.0)		
Severity of dysphagia at 4 weeks after the first cycle of SYS			179.84	<0.001 ^b
0	28 (24.6)	0 (0.0)		
1	72 (63.2)	0 (0.0)		
2	14 (12.3)	86 (75.4)		
3	0 (0.0)	28 (24.6)		
Severity of dysphagia at 8 weeks after the first cycle of SYS			136.22	<0.001 ^b
0	82 (71.9)	18 (15.8)		
1	32 (28.1)	11 (9.6)		
2	0 (0.0)	75 (65.8)		
3	0 (0.0)	10 (8.8)		

Data are presented as n (%).^a χ^2 test; ^bFisher's exact test. GTC, gastric transcatheter chemoembolization; SYS, systemic chemotherapy.

Table SII. Model coefficients for dysphagia.

Predictor	Estimate	95% CI	SE	Z	P-value	OR
Intercept	3.91930	0.99351-6.84509	1.49278	2.626	0.009	50.365
Sex (Male vs. female)	-0.85627	-1.91956-0.20703	0.54251	-1.578	0.114	0.425
Age (>60 vs. ≤60 years)	-0.05137	-0.94489-0.84215	0.45589	-0.113	0.910	0.950
ECOG (1+2 vs. 0)	-1.31706	-3.48861-0.85448	1.10795	-1.189	0.235	0.268
CEA (>5 vs. ≤5)	0.05640	-0.87489-0.98769	0.47516	0.119	0.906	1.058
CA 19-9 (>40 vs. ≤40)	-0.14255	-1.09925-0.81416	0.48812	-0.292	0.770	0.867
Grade of differentiation						
Poor vs. moderate	-0.23127	-1.56612-1.10358	0.68106	-0.340	0.734	0.794
Well vs. moderate	0.73782	-1.64522-3.12087	1.21586	0.607	0.544	2.091
Trastuzumab (Yes vs. no)	0.18783	-0.85935-1.23501	0.53429	0.352	0.725	1.207
First line chemotherapy regimen (XELOX vs. SOX)	-0.29227	-1.50001-0.91547	0.61621	-0.474	0.635	0.747
Second line chemotherapy regimen (Paclitaxel vs. irinotecan)	-0.75666	-1.71317-0.19985	0.48802	-1.550	0.121	0.469
Number of GTC (>2 vs. ≤2)	-0.90320	-1.88175-0.07534	0.49927	-1.809	0.070	0.405

Estimates represent the log odds of 'Dysphagia = No' vs. 'Dysphagia = Yes'. ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; XELOX, capecitabine + oxaliplatin; SOX, tegafur-gimeracil-oteracil + oxaliplatin; GTC, gastric transcatheter chemoembolization; CI, confidence interval; OR odds ratio.

Table SIII. Model fit measures.

Model	Deviance	AIC	BIC	McFadden's R ²	Cox & Snell's R ²	Nagelkerke's R ²
1	122.8319	146.8319	179.6663	0.0924477	0.1039478	0.1495793

AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion.

Table SIV. Omnibus likelihood ratio tests.

Predictor	χ^2	df	P-value
Sex	2.6720	1	0.102
Age	0.0127	1	0.910
ECOG	1.8381	1	0.175
CEA	0.0141	1	0.905
CA 19-9	0.0853	1	0.770
Grade of differentiation	0.7675	2	0.681
Trastuzumab	0.1245	1	0.724
First line chemotherapy regimen	0.2245	1	0.636
Second line chemotherapy regimen	2.4206	1	0.120
Number of GTC	3.4419	1	0.064

ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; GTC, gastric transcatheter chemoembolization.

Table SV. Univariate and multivariate analysis of predictive factors for 12-month survival rate of patients in the GTC+SYS group.

Characteristic	Total, n	Events, n	Univariate			Events, n	Multivariate		
			OR	95% CI	P-value		OR	95% CI	P-value
Sex									
Female	31	18	-	-		18	-	-	
Male	83	45	0.86	0.37, 1.97	0.713	45	0.91	0.36, 2.28	0.843
Age, years									
≤60	51	25	-	-		25	-	-	
>60	63	38	1.58	0.75, 3.33	0.229	38	1.59	0.72, 3.55	0.254
ECOG									
0	11	7	-	-		7	-	-	
1+2	103	56	0.68	0.19, 2.47	0.559	56	0.70	0.17, 2.87	0.620
CEA, ng/ml									
≤5	62	36	-	-		36	-	-	
>5	52	27	0.78	0.37, 1.64	0.512	27	0.71	0.31, 1.63	0.421
CA199, U/ml									
≤40	60	36	-	-		36	-	-	
>40	54	27	0.67	0.32, 1.40	0.284	27	0.73	0.31, 1.75	0.483
Grade of differentiation									
Moderate	25	18	-	-		18	-	-	
Poor	80	39	0.37	0.14, 0.98	0.046	39	0.58	0.17, 1.95	0.380
Well	9	6	0.78	0.15, 4.00	0.764	6	1.15	0.20, 6.57	0.873
Trastuzumab									
No	78	43	-	-		43	-	-	
Yes	36	20	1.02	0.46, 2.25	0.966	20	1.21	0.47, 3.15	0.692
First-line chemotherapy regimen									
SOX	73	35	-	-		35	-	-	
XELOX	41	28	2.34	1.05, 5.22	0.038	28	1.72	0.59, 5.00	0.320
Second-line chemotherapy regimen									
Irinotecan	72	42	-	-		42	-	-	
Paclitaxel	42	21	0.71	0.33, 1.54	0.389	21	0.75	0.31, 1.80	0.521
Number of GTCs									

≤2	49	23	-	-		23	-	-	
>2	65	40	1.81	0.85, 3.83	0.122	40	1.82	0.78, 4.28	0.168

OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; SOX, tegafur-gimeracil-oteracil + oxaliplatin; XELOX, capecitabine + oxaliplatin; GTC, gastric transcatheter chemoembolization; SYS, systemic chemotherapy,

Table SVI.Univariate and multivariate analysis of predictive factors for presence of dysphagia symptoms after 8 weeks of the first cycle of SYS for GTC+SYS group.

Characteristic	Total, n	Events, n	Univariate OR (95% CI)	P-value	Events, n	Multivariate OR(95% CI)	P-value
Sex							
Female	31	24	-		24	-	
Male	83	58	0.68 (0.26-1.77)	0.427	58	0.42 (0.15-1.23)	0.114
Age, years							
≤60	51	38	-		38	-	
>60	63	44	0.79 (0.35-1.81)	0.582	44	0.95 (0.39-2.32)	0.910
ECOG							
0	11	10	-		10	-	
1+2	103	72	0.23 (0.03-1.89)	0.173	72	0.27 (0.03-2.35)	0.235
CEA, ng/ml							
≤5	62	45	-		45	-	
>5	52	37	0.93 (0.41-2.11)	0.866	37	1.06 (0.42-2.69)	0.906
CA 19-9, U/ml							
≤40	60	45	-		45	-	
>40	54	37	0.73 (0.32-1.65)	0.443	37	0.87 (0.33-2.26)	0.770
Grade of differentiation							
Moderate	25	18	-		18	-	
Poor	80	56	0.91 (0.34-2.46)	0.848	56	0.79 (0.21-3.01)	0.734
Well	9	8	3.11 (0.33-29.66)	0.324	8	2.09 (0.19-22.67)	0.544
Trastuzumab							
No	78	56	-		56	-	
Yes	36	26	1.02 (0.42-2.46)	0.962	26	1.21 (0.42-3.44)	0.725
First line chemotherapy regimen							
SOX	73	53	-		53	-	
XELOX	41	29	0.91 (0.39-2.13)	0.831	29	0.75 (0.22-2.50)	0.635
Second line chemotherapy regimen							
Irinotecan	72	56	-		56	-	
Paclitaxel	42	26	0.46 (0.20-1.07)	0.072	26	0.47 (0.18-1.22)	0.121
Number of GTC							
≤2	49	40	-		40	-	
>2	65	42	0.41 (0.16-1.07)	0.055	42	0.41 (0.15-1.08)	0.070

OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; SOX, tegafur-gimeracil-oteracil + oxaliplatin; XELOX, capecitabine + oxaliplatin; GTC, gastric transcatheter chemoembolization, SYS: Systemic chemotherapy,

Table SVII. Comparison of adverse effects between two groups.

Adverse effect	GTC + SYS (n=114)		SYS (n=114)		P-value	
	Any grade	Grade 3/4	Any grade	Grade 3/4	Any grade ^a	Grade 3/4 ^b
Anemia	58 (51)	4 (3.6)	55(48)	3 (3.3)	0.791	>0.999
Leukopenia	35 (31)	8 (7.3)	35 (31)	6 (4.9)	>0.999	0.784
Neutropenia	41 (36)	8 (7.3)	50 (44)	11 (9.8)	0.279	0.633
Thrombocytopenia	29 (25)	6 (5.5)	32 (28)	9 (8.2)	0.765	0.595
ALT or AST increased	29 (25)	4 (3.6)	26 (23)	6 (4.9)	0.757	0.748
Serum creatinine increased	25 (22)	4 (3.6)	24 (21)	2 (1.6)	>0.999	0.683
Nausea and vomiting	60 (53)	8 (7.3)	50 (44)	6 (4.9)	0.234	0.784
Infection	2 (1.8)	0 (0.0)	4 (3.3)	0 (0)	0.683	>0.999
Diarrhea	15 (13)	2 (1.8)	9 (8.2)	3 (3.3)	0.280	>0.999
Anorexia	8 (7.3)	2 (1.8)	17 (15)	3 (3.3)	0.088	>0.999

Data are presented as n (%). ^a χ^2 test; ^bFisher's exact test. Grades were determined using the Common Terminology Criteria for Adverse Events v5.0. AST, aspartate aminotransferase; ALT, alanine aminotransferase; GTC, gastric transcatheter chemoembolization; SYS, systemic chemotherapy.